Femasys Inc (FEMY) FinancialsFEMYFemasys Inc

Femasys Inc (FEMY) generates its revenue primarily from Medical Equipment, Supplies & Distribution, which accounts for 100.0% of total sales, equivalent to $213.11K. Understanding this concentration is critical for investors evaluating how FEMY navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Femasys Inc maintains a gross margin of 32.12%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1526.66%, while the net margin is -1346.81%. These profitability ratios, combined with a Return on Equity (ROE) of -424.97%, provide a clear picture of how effectively FEMY converts its operational activities into shareholder value.

In the context of the broader market, FEMY competes directly with industry leaders such as WETH and CLWT. With a market capitalization of $11.56M, it holds a leading position in the sector. When comparing efficiency, FEMY's gross margin of 32.12% stands against WETH's 34.75% and CLWT's 28.82%. Such benchmarking helps identify whether Femasys Inc is trading at a premium or discount relative to its financial performance.

Femasys has shown fluctuating revenue, with Q4 2025 revenue at $729,394, but it has also reported significant net losses, such as -$4,469,095 in Q2 2026. The gross margin has varied, with a recent low of 32.12% in Q2 2026, indicating challenges in maintaining profitability.